Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGB101 for Parkinson's Disease Psychosis
NCT05824728Phase 2Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levetiracetam in Parkinson's disease (PD), sponsored by Johns Hopkins University. Started Sep 2023; status: active, not recruiting.
02
Drugs
levetiracetam
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05824728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824728.